Pharmacophore modeling technique applied for the discovery of proteasome inhibitors

Bibliography

• Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151-60
   PubMed Web of Science ®Google Scholar
• Navon A, Ciechanover A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 2009;284(49):33713-18
   PubMed Web of Science ®Google Scholar
• Löwe J, Stock D, Jap B, et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995;268(5210):533-9
   PubMed Web of Science ®Google Scholar
• Peters JM, Cejka Z, Harris JR, et al. Structural features of the 26 S proteasome complex. J Mol Biol 1993;234(4):932-7
   PubMed Web of Science ®Google Scholar
• Groll M, Ditzel L, Löwe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386(6624):463-71
   PubMed Web of Science ®Google Scholar
• Huber EM, Basler M, Schwab R, et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012;148:727-38
   PubMed Web of Science ®Google Scholar
• An W, Hwang S, Trepel J, Blagosklonny MV. Proteasenhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14(7):1276
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60
   PubMed Web of Science ®Google Scholar
• Almond J, Cohen G. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;16(4):433
   PubMed Web of Science ®Google Scholar
• Dror O, Shulman-Peleg A, Nussinov R, Wolfson HJ. Predicting molecular interactions in silico: I. a guide to pharmacophore identification and its applications to drug design. Curr Med Chem 2004;11:71-90
   PubMed Web of Science ®Google Scholar
• Van Drie JH. Monty kier and the origin of the pharmacophore concept. Internet Electron J Mol Des 2007;6:271-9
   Google Scholar
• Kier LB. Molecular orbital calculation of preferred conformations of acetylcholine, muscarine, and muscarone. Mol Pharmacol 1967;3(5):487-94
   PubMed Web of Science ®Google Scholar
• Kier LB. Molecular orbital theory in drug research. Academic Press, New York, NY, USA; 1971. p. 1-258
   Google Scholar
• Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1997). In: James AB, editor. Annual reports in medicinal chemistry. Academic Press; NY, USA; 1998. p. 385-95
   Google Scholar
• Shin WJ, Seong BL. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Expert Opin Drug Discov 2013;8(4):411-26
   PubMed Web of Science ®Google Scholar
• Pevzner Y, Metcalf R, Kantor M, et al. Recent advances in proteasome inhibitor discovery. Expert Opin Drug Discov 2013;8(5):537-68
   PubMed Web of Science ®Google Scholar
• Walters WP, Stahl MT, Murcko MA. Virtual screening-an overview. Drug Discov Today 1998;3(4):160-78
   Web of Science ®Google Scholar
• Shoichet BK. Virtual screening of chemical libraries. Nature 2004;432(7019):862-5
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004;3(11):935-49
   PubMed Web of Science ®Google Scholar
• Lavelin I, Beer A, Kam Z, et al. Discovery of novel proteasome inhibitors using a high-content cell-based screening system. PLoS One 2009;4(12):e8503
   PubMed Web of Science ®Google Scholar
• Blackburn C, Gigstad KM, Hales P, et al. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem J 2010;430(Pt 3):461
   PubMedGoogle Scholar
• Gallastegui N, Beck P, Arciniega M, et al. Hydroxyureas as noncovalent proteasome inhibitors. Angew Chem Int Ed 2012;51(1):247-9
   PubMed Web of Science ®Google Scholar
• Lower M, Proschak E. Structure-based pharmacophores for virtual screening. Mol Inf 2011;30(5):398-404
   Web of Science ®Google Scholar
• Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel 1998;1(1):4-15
   PubMedGoogle Scholar
• Ortuso F, Langer T, Alcaro S. GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. Bioinformatics 2006;22(12):1449-55
   PubMed Web of Science ®Google Scholar
• Foloppe N, Chen IJ. Conformational sampling and energetics of drug-like molecules. Curr Med Chem 2009;16(26):3381-413
   PubMed Web of Science ®Google Scholar
• Hahn M. Three-dimensional shape-based searching of conformationally flexible compounds. J Chem Inf Comput Sci 1997;37(1):80-6
   Google Scholar
• Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005;45(1):160-9
   PubMed Web of Science ®Google Scholar
• Dror O, Shulman-Peleg A, Nussinov R, Wolfson HJ. Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr Med Chem 2004;11(1):71-90
   PubMed Web of Science ®Google Scholar
• Tresadern G, Bemporad D. Modeling approaches for ligand-based 3D similarity. Future Med Chem 2010;2(10):1547-61
   PubMed Web of Science ®Google Scholar
• Kubinyi H. QSAR and 3D QSAR in drug design Part 1: methodology. Drug Discov Today 1997;2(11):457-67
   Web of Science ®Google Scholar
• Basse N, Montes M, Maréchal X, et al. Novel organic proteasome inhibitors identified by virtual and in vitro screening. J Med Chem 2010;53:509-13
   PubMed Web of Science ®Google Scholar
• Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007;107:687-717
   PubMed Web of Science ®Google Scholar
• Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012;19(1):99-115
   PubMed Web of Science ®Google Scholar
• Rentsch A, Landsberg D, Brodmann T, et al. Synthesis and pharmacology of proteasome inhibitors. Angew Chem Int Ed Engl 2013;52:5450-88
   PubMed Web of Science ®Google Scholar
• Stein ML, Groll M. Applied techniques for mining natural proteasome inhibitors. Biochim Biophys Acta 2014;1843:26-38
   PubMed Web of Science ®Google Scholar
• Screen M, Britton M, Downey SL, et al. Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem 2010;285(51):40125-34
   PubMed Web of Science ®Google Scholar
• Beck P, Dubiella C, Groll M. Covalent and non-covalent reversible proteasome inhibition. Biol Chem 2012;393(10):1101-20
   PubMed Web of Science ®Google Scholar
• Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-6
   PubMed Web of Science ®Google Scholar
• Britton M, Lucas MM, Downey SL, et al. Selective inhibitor of proteasome’s caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol 2009;16(12):1278-89
   PubMed Web of Science ®Google Scholar
• Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:7156-61
   Google Scholar
• Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tolls to drug candidates. Chem Biol 2001;8:739-58
   PubMed Web of Science ®Google Scholar
• Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71
   PubMed Web of Science ®Google Scholar
• Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotripsin-like activity of the pituitary multicatalityc proteinase complex. Biochemistry 1992;31:9421-8
   PubMed Web of Science ®Google Scholar
• Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8
   PubMed Web of Science ®Google Scholar
• Piva R, Ruggeri B, Williams M, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008;111(5):2765-75
   PubMed Web of Science ®Google Scholar
• Meng LH, Kwok BHB, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999;59:2798-801
   PubMed Web of Science ®Google Scholar
• Hanada M, Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 1992;45:1746-52
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67(13):6383-91
   PubMed Web of Science ®Google Scholar
• Bennet M, Kirk C. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Dev 2008;11(5):616
   PubMed Web of Science ®Google Scholar
• Grawert MA, Groll M. Exploiting nature’s rich source of proteasome inhibitors as starting points in drug development. Chem Commun 2012;48:1364-78
   PubMed Web of Science ®Google Scholar
• Bogyo M, McMaster JS, Gaczynska M, et al. Covalent modification of the active site Thr of proteasome beta-subunits and the E coli homologue HslV by a new class of inhibitors. Proc Natl Acad Sci USA 1997;94:6629-34
   PubMed Web of Science ®Google Scholar
• Maréchal X, Genin E, Sperandio O, et al. 1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome. Curr Med Chem 2013;20(18):2351-62
   PubMed Web of Science ®Google Scholar
• Desvergne A, Genin E, Maréchal X, et al. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. J Med Chem 2013;56:3367-78
   PubMed Web of Science ®Google Scholar
• Corey EJ, Li WD. Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull (Tokyo) 1999;47:1-10
   PubMed Web of Science ®Google Scholar
• Dick LR, Cruikshank AA, Greiner L, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin- a central role for clasto-lactacystin β-lactone. J Biol Chem 1996;271:7273-6
   PubMed Web of Science ®Google Scholar
• Kisselev AF, Songyang Z, Goldber AL. Why does threonine, and notserine, function as the active site nucleophile in proteasomes? J Biol Chem 2000;275:14831-7
   PubMed Web of Science ®Google Scholar
• Loidl G, Groll M, Musiol HJ, et al. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 1999;96:5418-22
   PubMed Web of Science ®Google Scholar
• Omura S, Fujimoto T, Otoguro K, et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) 1991;44:113-16
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F. MLN-519. Millennium/PAION. Curr Opin Investig Drugs 2003;4:333-41
   PubMedGoogle Scholar
• Fenical W, Jensen PR, Palladino MA, et al. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem 2009;17(6):2175-80
   PubMed Web of Science ®Google Scholar
• Groll M, Schellenberg B, Bachmann AS, et al. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 2008;452:755-8
   PubMed Web of Science ®Google Scholar
• Macherla VR, Mitchell SS, Manam RR, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005;48:3684-7
   PubMed Web of Science ®Google Scholar
• Potts B, Albitar M, Anderson K, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets 2011;11:254-84
   PubMed Web of Science ®Google Scholar
• Koguchi Y, Kohno J, Nishio M, et al. TMC-95A, B, C and D, novel proteasome inhibitors produced by Apiospora montagnei sacc. TC 1093. Taxonomy, production, isolation and biological activities. J Antibiot (Tokyo) 2000;53(2):105-9
   PubMed Web of Science ®Google Scholar
• Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001;311:543-8
   PubMed Web of Science ®Google Scholar
• Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol 2008;15:501-12
   PubMed Web of Science ®Google Scholar
• Williams AJ, Dave JR, Tortella FC. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 2006;49(2):106-12
   PubMed Web of Science ®Google Scholar
• Vogt VM. Ubiquitin in retrovirus assembly: actor or bystander. Proc Natl Acad Sci USA 2000;97:12945-7
   PubMed Web of Science ®Google Scholar
• Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999;274(50):35734-40
   PubMed Web of Science ®Google Scholar
• Qian K, Kim SY, Hung HY, et al. New betulinic acid derivatives as potent proteasome inhibitors. Bioorg Med Chem Lett 2011;21(19):5944-7
   PubMed Web of Science ®Google Scholar
• Calise J, Saul R. The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol 2013;304(3):H337-49
   PubMed Web of Science ®Google Scholar
• Yu X, Huang S, Patterson E, et al. Proteasome degradation of GRK2 during ischemia and ventricular tachyarrhythmias in a canine model of myocardial infarction. Am J Physiol Heart Circ Physiol 2005;289(5):H1960-7
   PubMed Web of Science ®Google Scholar
• Sureshkumar KK, Hussain SM, Marcus RJ, et al. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol 2012;77(3):246-53
   PubMed Web of Science ®Google Scholar
• Hideshima T, Neri P, Tassone P, et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006;12(19):5887-94
   PubMed Web of Science ®Google Scholar